Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00628901 · ClinicalTrials.gov registry record · Phase 4

A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

A Phase 4 study, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 4
Development phase
60
Enrollment target

NCT00628901 is a Phase 4 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00628901, a Phase 4 study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 4
Development phase
60 participants
Enrollment target

Study Summary

The purpose of this study is to demonstrate comparability between Contour SE™ Microspheres and Embosphere® Microspheres for achieving post UFE fibroid devascularization in women with symptomatic uterine fibroids.

Interventions

  • PROCEDURE Uterine Fibroid Embolization (UFE)
  • DEVICE Contour SE™ Microspheres
  • DEVICE Embosphere® Microspheres

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-01
Est. Completion 2011-01
Phase Phase 4

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00628901

The ClinicalTrials.gov registry entry for NCT00628901 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Uterine Fibroid Embolization (UFE) is the first listed.

NCT00628901 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00628901 about?

NCT00628901 is a clinical study titled "A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)". The purpose of this study is to demonstrate comparability between Contour SE™ Microspheres and Embosphere® Microspheres for achieving post UFE fibroid devascularization in women with symptomatic uterine fibroids.

What is the current status of trial NCT00628901?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2006-01. Estimated completion is 2011-01.

What interventions are being tested in trial NCT00628901?

The interventions under investigation include: Uterine Fibroid Embolization (UFE) (PROCEDURE), Contour SE™ Microspheres (DEVICE), Embosphere® Microspheres (DEVICE).

Who is sponsoring clinical trial NCT00628901?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.